Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the Chinese gastric cancer drug market will nearly triple between 2007 and 2012. According to the new Emerging Markets report entitled Gastric Cancer in China, this growth will be fueled by increased access to health insurance and greater patient spending power, leading to increased usage of targeted therapies. Additionally, the prevalence of gastric cancer in China is among the highest in the world. In 2007, approximately 392,000 cases were diagnosed in China, and it is forecasted that the indication population will grow 2.3 percent per year between 2007 and 2012.

The report also finds that Jiangsu Simcere's Endostar and Merck KGaA's Erbitux are the targeted therapies prescribed most often by Chinese physicians for the treatment of gastric cancer. These new targeted therapies will be prescribed to a greater percentage of the eligible population in China than in the past, benefiting from increased physician familiarity and better efficacy and toxicity profiles than conventional chemotherapy agents. More importantly, surveyed physicians anticipate that some targeted therapies will be included in the National Reimbursement Drug List (NRDL) by 2012, significantly increasing patient accessibility to these drugs.

"The Chinese government plans to insure close to 100 percent of the Chinese population by 2010 through three government-sponsored insurance schemes: Basic Medical Insurances (BMI), Urban Resident Basic Medical Insurance (URBMI) and new Rural Cooperative Medical Scheme (NCMS)," said Victor Li, Ph.D., analyst at Decision Resources. "These initiatives will increase gastric cancer diagnosis and drug-treatment rates in China and present an opportunity for multinational companies to reach a larger patient population."

Mr. Li will be conducting a webinar entitled "China's Gastric Cancer Drug Market to Nearly Triple by 2012: A Promising Market for Targeted Therapies" based on the report on April 24 at 10 a.m. EST. This will take an in-depth look at the report findings and is complementary to all purchasers of this report. If members of the media would like to attend, please contact Elizabeth Marshall at 781-296-2563 or

About Emerging Markets -- China

Emerging Markets -- China is the first and only syndicated report series focusing on high-growth emerging markets with comprehensive disease-specific analysis. With these reports, biopharmaceutical companies can accomplish the following:

  -- More accurately assess the commercial opportunity for Western brands in      key pharmaceutical markets of China -- Beijing, Shanghai, Guangzhou --      and in the high-growth second-tier markets of Tianjin, Wuhan, Nanjing,      Hangzhou, and Jinan.   -- Understand the physician treatment patterns and drivers of choice in      key first- and second-tier cities based on primary research.   -- Gain a clear perspective of the Chinese five-year market forecast at      the drug level, broken out by urban and rural areas, and by sales from      multinational and Chinese-based companies.     About Decision Resources 

Decision Resources, Inc., ( ) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563,

The Effect of Drugs from Novartis and Sanofi-Aventis on Mortality Rates Will Drive Prescription Decisions in Hypertension Treatment

View Now